Literature DB >> 28877534

Open Abdomen Improves Survival in Patients With Peritonitis Secondary to Acute Superior Mesenteric Artery Occlusion.

Weiwei Ding1, Kai Wang, Baochen Liu, Xinxin Fan, Shikai Wang, Jianmin Cao, Xingjiang Wu, Jieshou Li.   

Abstract

BACKGROUND: Damage control surgery and open abdomen (OA) have been extensively used in the severe traumatic patients. However, there was little information when extended to a nontrauma setting. The purpose of this study was to evaluate whether the liberal use of OA as a damage control surgery adjunct improved the clinical outcome in acute superior mesenteric artery occlusion patients. STUDY
DESIGN: A single-center, retrospective cohort review was performed in a national tertiary surgical referral center.
RESULTS: Forty-four patients received OA (OA group) and 65 patients had a primary fascial closure (non-OA group) after diagnosed as peritonitis secondary to acute superior mesenteric artery occlusion from January, 2005 to June, 2016. Revascularization was achieved through endovascular aspiration embolectomy, open embolectomy, or percutaneous stent. No difference of bowel resection length was found between groups in the first emergency surgery. However, more non-OA patients (35.4%) required a second-look enterectomy to remove the residual bowel ischemia than OA patients (13.6%, P<0.05). OA was closed within a median of 7 days (4 to 15 d). There was a mean of 134 cm residual alive bowel in OA, whereas 96 cm in non-OA. More non-OA patients suffered from intra-abdominal sepsis (23.1% vs. 6.8%, P<0.01), intra-abdominal hypertension (31% vs. 0, P<0.01), and acute renal failure (53.8% vs. 31.8%, P<0.05) than OA group after surgery. Short-bowel syndrome occurred infrequently in OA than non-OA patients (9.1% vs. 36.9%, P<0.01). OA significantly decreased the 30-day (27.3% vs. 52.3%, P<0.01) and 1-year mortality rate (31.8 % vs. 61.5%, P<0.01) compared with non-OA group.
CONCLUSIONS: Liberal use of OA, as a damage control adjunct avoided the development of intra-abdominal hypertension, reduced sepsis-related complication, and improved the clinical outcomes in peritonitis secondary to acute SMA occlusion.

Entities:  

Mesh:

Year:  2017        PMID: 28877534     DOI: 10.1097/MCG.0000000000000799

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  5 in total

1.  Surgical Outcomes in Acute Mesenteric Ischemia: Has Anything Changed Over the Years?

Authors:  María Asunción Acosta-Mérida; Joaquín Marchena-Gómez; Pedro Saavedra-Santana; José Silvestre-Rodríguez; Manuel Artiles-Armas; María Mar Callejón-Cara
Journal:  World J Surg       Date:  2020-01       Impact factor: 3.352

2.  Usefulness of damage control approach in patients with limited acute mesenteric ischemia: a prospective study of 85 patients.

Authors:  Antonio Brillantino; Michele Lanza; Massimo Antropoli; Alfonso Amendola; Simone Squillante; Vincenzo Bottino; Adolfo Renzi; Maurizio Castriconi
Journal:  Updates Surg       Date:  2021-10-22

3.  Predictors of irreversible intestinal resection in patients with acute mesenteric venous thrombosis.

Authors:  Shi-Long Sun; Xin-Yu Wang; Cheng-Nan Chu; Bao-Chen Liu; Qiu-Rong Li; Wei-Wei Ding
Journal:  World J Gastroenterol       Date:  2020-07-07       Impact factor: 5.742

4.  The Association of Coloproctology of Great Britain and Ireland consensus guidelines in emergency colorectal surgery.

Authors:  Andrew S Miller; Kathryn Boyce; Benjamin Box; Matthew D Clarke; Sarah E Duff; Niamh M Foley; Richard J Guy; Lisa H Massey; George Ramsay; Dominic A J Slade; James A Stephenson; Phil J Tozer; Danette Wright
Journal:  Colorectal Dis       Date:  2021-02       Impact factor: 3.917

5.  Accuracy of citrulline, I-FABP and D-lactate in the diagnosis of acute mesenteric ischemia.

Authors:  Alexandre Nuzzo; Kevin Guedj; Olivier Corcos; Katell Peoc'h; Sonja Curac; Claude Hercend; Claude Bendavid; Nathalie Gault; Alexy Tran-Dinh; Maxime Ronot; Antonino Nicoletti; Yoram Bouhnik; Yves Castier
Journal:  Sci Rep       Date:  2021-09-23       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.